A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects
Part of paid clinical trials in Cypress, California.
- Sponsor
- Centocor, Inc.
- Study ID
- NCT01258777
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy Volunteers
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Accepted
Interventions
- 400 mg golimumab or placebo — DRUGSingle dose of 400 mg subcutaneously
- 200 mg golimumab or placebo — DRUGSingle dose of 200 mg subcutaneously
Study Details
The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.
Key Dates
- Start date
- Oct 31, 2010
- Status verified
- Sep 2013
- Completion
- Apr 30, 2011
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 001200 mg golimumab or placebo Single dose of 200 mg subcutaneously
- Experimental: 002400 mg golimumab or placebo Single dose of 400 mg subcutaneously
Primary Outcome Measure
Pharmacokinetics (study of what the body does to the drug) of golimumab in Japanese and Caucasian Male subjects [ Time Frame: Week 12 (Day 78) ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| - | Cypress | California | - | - |
Related Studies
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Glendale, California
- A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseasePHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Birmingham, Alabama
- Blood Flow Restriction Training on Upper Extremity Grip StrengthRecruiting · Casa Colina Hospital and Centers for Healthcare · Pomona, California
- A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic HyperuricemiaPHASE1 · Recruiting · Novo Nordisk A/S · Glendale, California